课题基金 / 基金详情

TOPIC 453: A DIGITAL TOOL TO INTEGRATE CANCER PREVENTION WITHIN PRIMARY CARE.

TOPIC 453: A DIGITAL TOOL TO INTEGRATE CANCER PREVENTION WITHIN PRIMARY CARE.
主题 453:将癌症预防纳入初级保健的数字工具。
批准号:
10975542
负责人:
GRACE CHEN
金额:
$0.66万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-08-31 至 2024-08-30

项目摘要

项目成果

GRACE CHEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
LucidAct Inc. (LucidAct) is a Digital Health company that offers connected telemedicine and Remote Patient Monitoring (RPM) solutions specifically designed for patients that are non-tech savvy, living in rural areas, or having cultural and/or language barriers. We provide an end-to-end remote care management solution that combines connected medical devices, telehealth, and intelligent patient engagement into a single solution for healthcare organizations. LucidAct platform is cost effective, responsive, and user-friendly for all end-users, including patients, nurses, and physicians. Under this NCI contract, LucidAct will develop a digital tool for cancer prevention, in which we will identify patients that are at high-risk by assessing all potential risk factors including family history, genetics, and environmental factors (tobacco use, diet, obesity, etc.). We will offer science- and guideline-based recommendations to patients to engage in lifestyle changes to reduce cancer risk. LucidAct’s innovative workflow engine is customizable and configurable to manage complex care and to personalize recommendations to each individual patient. We have a team of healthcare and technology professionals that integrate expertise and healthcare data with PCP care and patient expectations to implement smart and usable solutions to complement and extend patient engagement beyond in-person visits.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TOPIC 453: A DIGITAL TOOL TO INTEGRATE CANCER PREVENTION WITHIN PRIMARY CARE Moonshot support
  • 批准号:
    10929760
  • 项目类别:
  • 资助金额:
    $39.3万
  • 财政年份:
    2023
  • 负责人:
    GRACE CHEN
  • 依托单位:
    --
国内基金
海外基金
扶正消癥汤对乳腺癌MCF-7、MDA-MB453、MDA-MB231细胞亚结构及h-TERT表达的影响
  • 批准号:
    2022J011334
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    钱之远
  • 依托单位:
胃癌中PIK3CA非热点突变E453K上调PD-L1的机制研究
  • 批准号:
    81672397
  • 项目类别:
    面上项目
  • 资助金额:
    57.0万元
  • 批准年份:
    2016
  • 负责人:
    勾红峰
  • 依托单位:
黑米花青素对HER-2/neu高表达乳腺癌血管生成的抑制作用及机理研究